S
CGEM icon

SignatureFD’s Cullinan Oncology CGEM Stock Holding History

SignatureFD’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58.4K Sell
3,207
-2,343
-42% -$34.8K ﹤0.01% 1775
2026
Q1 		$78.9K Buy
5,550
+1,420
+34% +$18.2K ﹤0.01% 1467
2025
Q4 		$42.7K Buy
4,130
+3,607
+690% +$32.5K ﹤0.01% 1745
2025
Q3 		$3.1K Buy
523
+134
+34% +$981 ﹤0.01% 2822
2025
Q2 		$2.93K Buy
389
+157
+68% +$1.26K ﹤0.01% 2763
2025
Q1 		$1.76K Sell
232
-219
-49% -$2.1K ﹤0.01% 2909
2024
Q4 		$5.49K Hold
451
– – ﹤0.01% 2572
2024
Q3 		$7.55K Hold
451
– – ﹤0.01% 2447
2024
Q2 		$7.87K Hold
451
– – ﹤0.01% 2367
2024
Q1 		$7.68K Sell
451
-407
-47% -$6.29K ﹤0.01% 2404
2023
Q4 		$8.74K Buy
858
+254
+42% +$2.25K ﹤0.01% 2320
2023
Q3 		$5.47K Buy
+604
New +$6.29K ﹤0.01% 2457
2023
Q2 		– Sell
-171
Closed -$1.75K – 3256
2023
Q1 		$1.75K Buy
+171
New +$1.89K ﹤0.01% 2839
2022
Q4 		– Sell
-64
Closed -$1K – 3304
2022
Q3 		$1K Buy
64
+24
+60% +$323 ﹤0.01% 2926
2022
Q2 		$1K Buy
+40
New +$454 ﹤0.01% 2884
2021
Q3 		– Sell
-29
Closed -$1K – 3058
2021
Q2 		$1K Buy
+29
New +$892 ﹤0.01% 2696

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

SignatureFD's CGEM Position: Q2 2026 in Review

SignatureFD reduced its Cullinan Oncology (CGEM) stake by 42% in Q2 2026, selling an estimated $34.8K and leaving 3,207 shares worth $58.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1775.

SignatureFD first reported a position in CGEM in Q2 2021 and has held it in 16 quarters since. The position peaked at $78.9K in Q1 2026. 183 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • SignatureFD held 3,207 shares of Cullinan Oncology worth $58.4K as of Q2 2026.
  • SignatureFD sold 2,343 Cullinan Oncology shares in Q2 2026, an estimated $34.8K.
  • Cullinan Oncology made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #1775 holding.
  • SignatureFD first reported a position in Cullinan Oncology in Q2 2021 and has held it in 16 quarters since.
  • SignatureFD's Cullinan Oncology position peaked at $78.9K in Q1 2026.
  • 183 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.